|
gptkbp:instanceOf
|
gptkb:arylcyclohexylamine
dissociative anesthetic
|
|
gptkbp:analogue_of
|
gptkb:methoxetamine
gptkb:ketamine
|
|
gptkbp:binding_target
|
gptkb:NMDA_receptor
|
|
gptkbp:CASNumber
|
4631-27-0
|
|
gptkbp:category
|
NMDA receptor antagonist
substance abuse
recreational drug
|
|
gptkbp:chemicalFormula
|
C13H17NO2
|
|
gptkbp:color
|
white
|
|
gptkbp:effect
|
dissociation
euphoria
hallucinations
analgesia
|
|
gptkbp:firstReported
|
1960s
|
|
gptkbp:form
|
crystal
powder
|
|
gptkbp:hasStreet
|
gptkb:PMK
Para-Methoxy K
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Para-Methoxy Ketamine
|
|
gptkbp:IUPACName
|
2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone
|
|
gptkbp:legalStatus
|
controlled substance in some countries
|
|
gptkbp:molecularWeight
|
219.28 g/mol
|
|
gptkbp:not_approved_for_medical_use
|
true
|
|
gptkbp:otherName
|
gptkb:PMK
2-MeO-2'-Oxo-PCE
methoxyketamine
|
|
gptkbp:potential_risk
|
addiction
psychosis
bladder toxicity
|
|
gptkbp:relatedTo
|
gptkb:methoxetamine
gptkb:ketamine
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intranasal
|
|
gptkbp:sideEffect
|
confusion
nausea
tachycardia
urinary tract symptoms
|
|
gptkbp:structure
|
methoxy group
aryl group
cyclohexanone ring
|
|
gptkbp:studiedBy
|
gptkb:pharmacy
toxicology
|
|
gptkbp:usedFor
|
recreational drug
|
|
gptkbp:bfsParent
|
gptkb:PMK
|
|
gptkbp:bfsLayer
|
5
|